MetaCap

Celldex Therapeutics (CLDX) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova (TKNO) has outperformed Celldex Therapeutics (CLDX) over the past year, gaining 77.4% versus a gain of 5.8%. Over five years, CLDX leads with a -30.8% price change compared with -63.6% for TKNO. Celldex Therapeutics is the larger company by market cap ($2.15 billion vs $480.0 million), about 4.5 times the size, while Alpha Teknova is growing revenue faster (+7.4% vs -78.0%).

Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -16748.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLDX+5.79%TKNO+77.44%
+126%+32%-62%
Nov 21, 20251 yearNov 20, 2026
CLDX-36.20%TKNO-69.50%
+27%-37%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLDX versus TKNO key metrics
MetricCLDXTKNO
Share price$27.42$7.63
Market cap$2.15B$479.95M
1-day change-1.93%-2.30%
YTD return+0.96%+100.79%
1-year return+5.79%+77.44%
5-year return-30.78%-63.63%
EPS (TTM)$-4.29$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54M$40.52M
Revenue growth (YoY)-77.99%+7.35%
Net income (latest FY)$-258.76M$-17.26M
Gross margin87.06%33.17%
Operating margin-18599.81%-41.90%
Net margin-16748.03%-42.59%
52-week high$45.14$9.48
52-week low$22.33$1.91
Distance from 52-week high-39.26%-19.51%
Analyst consensusstrong_buynone
Avg. price target upside+133.41%+28.83%
Average volume1.33M437.31K
Shares outstanding78.55M62.90M
Employees198158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Celldex Therapeutics is about 4.5 times larger than Alpha Teknova by market value ($2.15B vs $479.95M).
  • TKNO has outperformed CLDX by 71.7 percentage points over the past year.
  • Alpha Teknova is more profitable, keeping -42.6 cents of every revenue dollar as net income versus -16748.0 cents for Celldex Therapeutics.
  • Alpha Teknova grew revenue faster in its latest fiscal year (+7.35% vs -77.99%).

About Celldex Therapeutics

CLDX stock →

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

CLDX vs TKNO FAQ

Which is bigger, Celldex Therapeutics or Alpha Teknova?

Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.15B compared with $479.95M for Alpha Teknova (TKNO).

Which stock has performed better over the past year, CLDX or TKNO?

TKNO returned +77.44% over the past 12 months, compared with +5.79% for CLDX (price return, excluding dividends). Past performance does not predict future results.

Are Celldex Therapeutics and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons